Source comparison
BPC-157 KPV for Gut Inflammation: Comparison
BPC-157 Angiogenesis & epithelial repair VEGF-R2 activation, FAK upregulation, NO pathway modulation Subcutaneous or oral 250–1000 mcg daily Rebuilds damaged intestinal lining through vascular growth and cell migration. Addresses structural damage KPV NF-κB in
This comparison does not assign a generated winner or score.
- BPC-157
- Angiogenesis & epithelial repair
- VEGF-R2 activation, FAK upregulation, NO pathway modulation
- Subcutaneous or oral
- 250–1000 mcg daily
- Rebuilds damaged intestinal lining through vascular growth and cell migration. Addresses structural damage
- KPV
- NF-κB inhibition & antimicrobial
- Blocks NF-κB nuclear translocation, reduces TNF-α/IL-6 transcription
- Oral (enteric-coated preferred)
- 500–2500 mcg daily
- Suppresses inflammatory gene expression and pathogenic bacterial growth. Addresses immune dysregulation
- Combined Protocol
- Dual-pathway modulation
- Tissue repair + immune signalling suppression
- BPC-157 subcutaneous, KPV oral
- BPC 250–500 mcg, KPV 1000–2000 mcg
- Targets both structural damage and inflammatory cascade simultaneously. Non-redundant mechanisms